Fulcrum Therapeutics, Inc. (FULC)
Oxford Ledge is still expanding full research coverage of FULC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A rare disease gene therapy company competing with larger firms and dependent on contract manufacturers for early-stage development.
SEC filings
- 8-K Costs for exit or disposal activities; Other material event 2026-06-04
- 8-K Other material event; Financial statements and exhibits 2026-06-01
- DEF 14A Proxy statement for shareholder vote 2026-04-30
- 10-Q Quarterly financial report (unaudited) 2026-04-27
- 8-K Termination of material agreement; Results of operations / financial condition; Departure/election of directors or officers; Financial statements and exhibits 2026-04-27
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for FULC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open FULC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.